Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Approvals Don’t Quit: Chantix Clears FDA For Smoking Cessation

This article was originally published in The Pink Sheet Daily

Executive Summary

Advantage of varenicline over GSK’s Zyban is more pronounced over the short-term than long-term.

You may also be interested in...



Nicotine Hits Smokers’ Bloodstreams In Seconds – Clock On Latest US NRT Approval Is At 17 Years

Gum, lozenge and patch NRTs available in US need as much as 30 minutes to deliver nicotine to users’ bloodstreams. Cigarettes are "purposely designed because of inhalation of smoke to deliver nicotine to the receptors in the brain in less than 10 seconds,” says former FDA tobacco programs chief Mitch Zeller.

NICE Recommends Cost Effectiveness Of Pfizer’s Smoking Cessation Drug

Varenicline is superior to nicotine replacement therapy and bupropion in achieving continuous abstinence, NICE determines.

NICE Recommends Cost Effectiveness Of Pfizer’s Smoking Cessation Drug

Varenicline is superior to nicotine replacement therapy and bupropion in achieving continuous abstinence, NICE determines.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel